美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

新橋生物

4.10

-0.1200-2.84%

成交量：2.78萬

成交額：11.50萬

市值：4.73億

市盈率：-8.36

高：4.32

開：4.18

低：4.10

收：4.22

52周最高：6.79

52周最低：0.5950

股本：1.15億

流通股本：4,823.40萬

量比：4.31

換手率：0.06%

股息：- -

股息率：- -

每股收益(TTM):-0.4902

每股收益(LYR):-0.2738

淨資產收益率：-18.46%

總資產收益率：-10.36%

市淨率：2.40

市盈率(LYR):-14.97

資料載入中...

總覽公司新聞公告

新橋生物盤中異動快速上漲5.75%

醫藥界「泡泡瑪特」：遞表港交所

新橋生物遞表港交所，主要專注於開發自主研發的創新型精準免疫腫瘤藥物

I-MAB（Nasdaq: IMAB）正式更名為新橋生物（NovaBridge Biosciences；Nasdaq: NBP），股票交易將於2025年10月30日正式生效，新品牌標誌着其向全球生物科技平台型公司的戰略轉型

I-Mab （納斯達克：IMAB）將於2025年10月30日轉型為Novabridge Biosciences （納斯達克：NBP），全新品牌和標誌將體現向全球生物科技平台的戰略轉型

Biotech資產出海迎多重「大考」：交易條款裏的長期挑戰

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NBP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新橋生物","latestPrice":4.1,"timestamp":1763044523076,"preClose":4.22,"halted":0,"volume":27843,"delay":0,"floatShares":48234000,"shares":115266053,"eps":-0.490217,"marketStatus":"交易中","change":-0.12,"latestTime":"11-13 09:35:46 EST","open":4.18,"high":4.3182,"low":4.1,"amount":114980.2411932,"amplitude":0.051706,"askPrice":4.18,"askSize":600,"bidPrice":4.12,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-0.490217,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1763067600000},"marketStatusCode":2,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":4.22,"preHourTrading":{"tag":"盘前","latestPrice":4.28,"preClose":4.22,"latestTime":"09:29 EST","volume":115,"amount":492.30005,"timestamp":1763044199098},"postHourTrading":{"tag":"盘后","latestPrice":4.3,"preClose":4.22,"latestTime":"19:23 EST","volume":1393,"amount":5929.79,"timestamp":1762993425542},"volumeRatio":4.313947,"impliedVol":1.028,"impliedVolPercentile":0.1818},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":48234000,"roa":"-10.36%","roe":"-18.46%","lyrEps":-0.273814,"volumeRatio":4.313947,"shares":115266053,"dividePrice":0,"high":4.3182,"amplitude":0.051706,"preClose":4.22,"low":4.1,"week52Low":0.595,"pbRate":"2.40","week52High":6.79,"institutionHeld":0,"latestPrice":4.1,"committee":-0.333333,"eps":-0.490217,"divideRate":0,"volume":27843,"delay":0,"ttmEps":-0.490217,"open":4.18,"prevYearClose":0.85,"prevWeekClose":4,"prevMonthClose":4.95,"prevQuarterClose":3.78,"fiveDayClose":4.19,"twentyDayClose":6.56,"sixtyDayClose":4.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"NBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2024-08-28","symbol":"NBP","fiscalQuarterEnding":"2024/06","expectedEps":-0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"pre","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1759467600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2025-11-11","current":-8.608433,"percent":0.428571,"low":-14.267741,"twenty":-13.374206,"median":-12.336552,"eighty":-12.157844,"high":-11.529488,"avg":-12.686039,"sd":0.832706,"marketCap":494491367},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-11","current":-12.365376,"twenty":-13.374206,"median":-12.336552,"eighty":-12.157844,"marketCap":494491367}],"updateTime":1763018270257},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582368829","title":"新橋生物盤中異動 快速上漲5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582368829?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 22:38","pubTimestamp":1762785528,"startTime":"0","endTime":"0","summary":"北京时间2025年11月10日22时38分，新桥生物股票出现异动，股价快速拉升5.75%。截至发稿，该股报4.23美元/股，成交量1.2826万股，换手率0.01%，振幅0.71%。新桥生物股票所在的生物技术行业中，整体涨幅为0.62%。其相关个股中，Cogent Biosciences, Inc.、Inflarx N.V.、Pluri Inc.涨幅较大，Inflarx N.V.、Propanc Biopharma, Inc.、Innate Pharma较为活跃，换手率分别为78.22%、15.29%、8.71%，振幅较大的相关个股有Cogent Biosciences, Inc.、Pluri Inc.、Inflarx N.V.，振幅分别为20.18%、20.06%、17.89%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110223848a49788fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110223848a49788fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2580280025","title":"醫藥界「泡泡瑪特」：遞表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2580280025","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580280025?lang=zh_tw&edition=fundamental","pubTime":"2025-11-02 08:02","pubTimestamp":1762041764,"startTime":"0","endTime":"0","summary":"VIS-101已在美国和中国完成了初步的安全性和剂量递增研究，目前正在中国完成一项随机剂量范围的II期研究。VIS-101预计将于2026年具备开展III期试验的条件。此次收购已通过新成立的子公司Visara完成的。“我们要做医药行业的‘泡泡玛特’。”傅唯用一个生动的比喻解释，泡泡玛特的核心是“连接设计师与全球渠道”，新桥要做的是“连接中国创新药研发者与全球市场”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102080748a481f874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102080748a481f874&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4195","NBP","BK4211","PFS"],"gpt_icon":0},{"id":"2579102884","title":"新橋生物遞表港交所，主要專注於開發自主研發的創新型精準免疫腫瘤藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2579102884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579102884?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 07:14","pubTimestamp":1761866058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所10月31日披露，新桥生物向港交所主板提交上市申请书，高盛和中信证券为联席保荐人。招股书显示，新桥生物成立于2016年，是一家采用不限治疗领域发展策略的全球性生物技术平台公司。自成立以来，公司主要专注于开发自主研发的创新型精准免疫肿瘤药物，用于癌症治疗。除givastomig外，截至最后实际可行日期， 新桥生物已建立包含三个临床阶段项目的管线，包括两个肿瘤项目uliledlimab及ragistomig，以及眼科项目VIS-101。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91167","NBP"],"gpt_icon":0},{"id":"2579907397","title":"I-MAB（Nasdaq: IMAB）正式更名為新橋生物（NovaBridge Biosciences；Nasdaq: NBP），股票交易將於2025年10月30日正式生效，新品牌標誌着其向全球生物科技平台型公司的戰略轉型","url":"https://stock-news.laohu8.com/highlight/detail?id=2579907397","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579907397?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 21:56","pubTimestamp":1761746160,"startTime":"0","endTime":"0","summary":"此项更名决议已获得公司于2025年10月24日召开的特别股东大会高票通过，并获董事会批准。在部分第三方网站或应用程序上，若搜索\"NovaBridge Biosciences\"或\"NBP\"时，可能暂时无法查询到公司美国存托股份在2025年10月30日之前的历史交易数据。我们正积极推进givastomig全球随机对照 II 期研究，预计于2026年第一季度完成首例患者入组。VIS-101预计将于2026年具备开展III期试验的条件。此次收购已通过新成立的子公司Visara完成。新桥生物成为Visara的控股股东，并拥有VIS-101的全球权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4810152_ZH10152_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4526","BK4505","NVIW.SI","BK4139","PSQ","USAW.SI","QID","TQQQ","BK4535","NQmain","USJW.SI","MNQmain","NBP","IMAB","MAB","SQQQ","QLD","TSYW.SI",".IXIC"],"gpt_icon":1},{"id":"1176185820","title":"I-Mab （納斯達克：IMAB）將於2025年10月30日轉型為Novabridge Biosciences （納斯達克：NBP），全新品牌和標誌將體現向全球生物科技平台的戰略轉型","url":"https://stock-news.laohu8.com/highlight/detail?id=1176185820","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176185820?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 21:03","pubTimestamp":1761742984,"startTime":"0","endTime":"0","summary":"I-Mab（纳斯达克：IMAB）将于2025年10月30日转型为Novabridge Biosciences（纳斯达克：NBP），全新品牌和标志将体现向全球生物科技平台的战略转型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP","BK4535","BK4526","BK4505","IMAB"],"gpt_icon":0},{"id":"2579390406","title":"Biotech資產出海迎多重「大考」：交易條款裏的長期挑戰","url":"https://stock-news.laohu8.com/highlight/detail?id=2579390406","media":"研发客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579390406?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 05:00","pubTimestamp":1761685247,"startTime":"0","endTime":"0","summary":"中国Biotech企业应充分认识到NewCo交易的“两步走”本质。《美国优先投资政策》对中国创新药行业的实际影响，最终仍取决于落地的具体细则，中国Biotech行业应当密切关注动向。许可交易频传利好，但签约只是起点据研发客统计，2022年以来中国创新药资产许可交易已达522起。其中不乏百利天恒与BMS的潜在交易总额达84亿美元的合作，成为近年来中国Biotech资产出海的标杆案例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029050226a47a598b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029050226a47a598b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","NBP","IMAB","BK4526","BK4139","NDAA","BK4215","BK4505","CSR"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}